Insmed (NASDAQ: INSM) plans J.P. Morgan Healthcare Conference presentation and webcast

Rhea-AI Filing Summary

Insmed Incorporated reported that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). The company will provide a live webcast of the presentation through the investor relations section of its website, allowing broader access for interested stakeholders. In connection with this conference appearance, Insmed issued a press release and prepared a slide presentation, which are included as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference for informational purposes but are not deemed filed under securities laws.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000110450600011045062026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

INSMED INCORPORATED

(Exact name of registrant as specified in its charter)

Virginia	000-30739	54-1972729
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

700 US Highway 202/206 Bridgewater, New Jersey		08807 (Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code: (908) 977-9900

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	INSM	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01 — Regulation FD Disclosure.

As previously announced, management of Insmed Incorporated (the “Company”) will present at the 44^th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). A live webcast of the presentation will be accessible through the investor relations section of the Company’s website. On January 9, 2026, in connection with the presentation, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. The slide presentation to be used during the presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 – Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Insmed Incorporated on January 9, 2026.
99.2		Insmed Incorporated J.P. Morgan Healthcare Conference Presentation.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 9, 2026	INSMED INCORPORATED
	By:	/s/ Michael A. Smith
	Name:	Michael A. Smith
	Title:	Chief Legal Officer and Corporate Secretary

FAQ

What event did Insmed (INSM) disclose in this 8-K?

Insmed disclosed that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, and that related materials are available.

When is Insmed’s J.P. Morgan Healthcare Conference presentation scheduled?

The presentation is scheduled for January 12, 2026, at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time).

How can investors access Insmed’s J.P. Morgan presentation?

A live webcast of the presentation will be accessible through the investor relations section of Insmed’s website.

What exhibits did Insmed include with this 8-K filing?

Insmed included a press release as Exhibit 99.1, a J.P. Morgan Healthcare Conference slide presentation as Exhibit 99.2, and a Cover Page Interactive Data File as Exhibit 104.

Are the Insmed press release and slides considered filed with the SEC?

The company stated that the information in Item 7.01, including Exhibits 99.1 and 99.2, is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference into other filings unless specifically referenced.

Who signed the Insmed (INSM) 8-K related to the J.P. Morgan conference?

The report was signed on behalf of Insmed Incorporated by Michael A. Smith, Chief Legal Officer and Corporate Secretary.